Tyler Van Buren
Stock Analyst at TD Cowen
(2.51)
# 2,326
Out of 5,152 analysts
62
Total ratings
48%
Success rate
2.17%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Buy | $120 → $85 | $38.57 | +120.38% | 1 | Feb 26, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $35 | $23.97 | +46.02% | 1 | Feb 26, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $40 → $45 | $57.33 | -21.51% | 3 | Feb 13, 2026 | |
| CCCC C4 Therapeutics | Initiates: Buy | n/a | $3.03 | - | 1 | Dec 2, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $15 | $10.31 | +45.49% | 3 | Nov 5, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | n/a | $31.44 | - | 1 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $30 → $40 | $27.31 | +46.47% | 2 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $95 | $66.17 | +43.57% | 2 | Oct 30, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $115 → $125 | $145.14 | -13.88% | 6 | Oct 23, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | n/a | $33.03 | - | 1 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $60.37 | - | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $11.71 | - | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $18.50 | - | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $33.17 | - | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $70 → $60 | $53.83 | +11.46% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $5.74 | - | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $6.88 | - | 1 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,030 → $1,200 | $764.93 | +56.88% | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $27.85 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $30.14 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $40.59 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $114.36 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $70.92 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.38 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $31.98 | +118.89% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.19 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.72 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $34.54 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $11.33 | +1,885.88% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $6.66 | +13,038.14% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $15.22 | +162.81% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $13.58 | +120.91% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.29 | +3,775.97% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.52 | +5,649.33% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.49 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $31.75 | - | 1 | Aug 4, 2017 |
Soleno Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $120 → $85
Current: $38.57
Upside: +120.38%
Arcutis Biotherapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $30 → $35
Current: $23.97
Upside: +46.02%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Hold
Price Target: $40 → $45
Current: $57.33
Upside: -21.51%
C4 Therapeutics
Dec 2, 2025
Initiates: Buy
Price Target: n/a
Current: $3.03
Upside: -
Biohaven
Nov 5, 2025
Maintains: Buy
Price Target: $50 → $15
Current: $10.31
Upside: +45.49%
MBX Biosciences
Nov 4, 2025
Initiates: Buy
Price Target: n/a
Current: $31.44
Upside: -
Travere Therapeutics
Oct 31, 2025
Maintains: Buy
Price Target: $30 → $40
Current: $27.31
Upside: +46.47%
BridgeBio Pharma
Oct 30, 2025
Maintains: Buy
Price Target: $60 → $95
Current: $66.17
Upside: +43.57%
Gilead Sciences
Oct 23, 2025
Maintains: Buy
Price Target: $115 → $125
Current: $145.14
Upside: -13.88%
IDEAYA Biosciences
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $33.03
Upside: -
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $60.37
Upside: -
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $11.71
Upside: -
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $18.50
Upside: -
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $33.17
Upside: -
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $53.83
Upside: +11.46%
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $5.74
Upside: -
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $6.88
Upside: -
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $764.93
Upside: +56.88%
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $27.85
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $30.14
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $40.59
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $114.36
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $70.92
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.38
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $31.98
Upside: +118.89%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.19
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.72
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $34.54
Upside: -
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $11.33
Upside: +1,885.88%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $6.66
Upside: +13,038.14%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $15.22
Upside: +162.81%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $13.58
Upside: +120.91%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.29
Upside: +3,775.97%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $0.52
Upside: +5,649.33%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $11.49
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $31.75
Upside: -